Programmatic management of rifampicin-resistant tuberculosis with standard regimen in Cameroon: a retrospective cohort study
To describe treatment outcomes for rifampicin-resistant tuberculosis (Rr-TB) started on standard regimen and the frequency of acquired drug resistance in patients treated using the standard treatment regimen (STR) in Cameroon between 2015-2019. This is a retrospective cohort study. Rr-TB patients we...
Uloženo v:
| Vydáno v: | International journal of infectious diseases Ročník 124; s. 81 - 88 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Elsevier Ltd
01.11.2022
Elsevier |
| Témata: | |
| ISSN: | 1201-9712, 1878-3511, 1878-3511 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | To describe treatment outcomes for rifampicin-resistant tuberculosis (Rr-TB) started on standard regimen and the frequency of acquired drug resistance in patients treated using the standard treatment regimen (STR) in Cameroon between 2015-2019.
This is a retrospective cohort study. Rr-TB patients were initiated on the STR, including a fluoroquinolone (FQ), a second-line injectable drug (SLI), and companion drugs. In case of resistance to fluoroquinolones (FQr) at baseline, FQ, SLI and ethionamide were replaced by bedaquiline, delamanid, and linezolid in a modified treatment regimen (mTR), FQr-mTR. In case of resistance to SLI (SLIr) at baseline, SLI was replaced by linezolid (LZD), SLIr-mTR. Logistic regression and competing risk regression were used to estimate predictors of early (first eight weeks) mortality and overall mortality, respectively.
Of 709 patients started on a standard regimen, treatment success occurred in 84.7% (587/693), 72.7% (8/11) and 100% (10/10) of patients treated with STR, FQr-mTR and SLIr-mTR as final regimens, respectively. Three (0.6%) patients acquired FQr during treatment. Early mortality occurred in 4.1% (29/709) and was associated with being HIV positive, male sex and being underweight. Overall mortality was associated with missing drug-susceptibility testing results at baseline, being HIV positive, age>40 and male sex.
Programmatic management of Rr-TB, with additional second-line drug resistance treated with mTR, resulted in excellent treatment outcomes. |
|---|---|
| AbstractList | Objectives: To describe treatment outcomes for rifampicin-resistant tuberculosis (Rr-TB) started on standard regimen and the frequency of acquired drug resistance in patients treated using the standard treatment regimen (STR) in Cameroon between 2015-2019. Methods: This is a retrospective cohort study. Rr-TB patients were initiated on the STR, including a fluoroquinolone (FQ), a second-line injectable drug (SLI), and companion drugs. In case of resistance to fluoroquinolones (FQr) at baseline, FQ, SLI and ethionamide were replaced by bedaquiline, delamanid, and linezolid in a modified treatment regimen (mTR), FQr-mTR. In case of resistance to SLI (SLIr) at baseline, SLI was replaced by linezolid (LZD), SLIr-mTR. Logistic regression and competing risk regression were used to estimate predictors of early (first eight weeks) mortality and overall mortality, respectively. Results: Of 709 patients started on a standard regimen, treatment success occurred in 84.7% (587/693), 72.7% (8/11) and 100% (10/10) of patients treated with STR, FQr-mTR and SLIr-mTR as final regimens, respectively. Three (0.6%) patients acquired FQr during treatment. Early mortality occurred in 4.1% (29/709) and was associated with being HIV positive, male sex and being underweight. Overall mortality was associated with missing drug-susceptibility testing results at baseline, being HIV positive, age>40 and male sex. Conclusion: Programmatic management of Rr-TB, with additional second-line drug resistance treated with mTR, resulted in excellent treatment outcomes. To describe treatment outcomes for rifampicin-resistant tuberculosis (Rr-TB) started on standard regimen and the frequency of acquired drug resistance in patients treated using the standard treatment regimen (STR) in Cameroon between 2015-2019. This is a retrospective cohort study. Rr-TB patients were initiated on the STR, including a fluoroquinolone (FQ), a second-line injectable drug (SLI), and companion drugs. In case of resistance to fluoroquinolones (FQr) at baseline, FQ, SLI and ethionamide were replaced by bedaquiline, delamanid, and linezolid in a modified treatment regimen (mTR), FQr-mTR. In case of resistance to SLI (SLIr) at baseline, SLI was replaced by linezolid (LZD), SLIr-mTR. Logistic regression and competing risk regression were used to estimate predictors of early (first eight weeks) mortality and overall mortality, respectively. Of 709 patients started on a standard regimen, treatment success occurred in 84.7% (587/693), 72.7% (8/11) and 100% (10/10) of patients treated with STR, FQr-mTR and SLIr-mTR as final regimens, respectively. Three (0.6%) patients acquired FQr during treatment. Early mortality occurred in 4.1% (29/709) and was associated with being HIV positive, male sex and being underweight. Overall mortality was associated with missing drug-susceptibility testing results at baseline, being HIV positive, age>40 and male sex. Programmatic management of Rr-TB, with additional second-line drug resistance treated with mTR, resulted in excellent treatment outcomes. To describe treatment outcomes for rifampicin-resistant tuberculosis (Rr-TB) started on standard regimen and the frequency of acquired drug resistance in patients treated using the standard treatment regimen (STR) in Cameroon between 2015-2019.OBJECTIVESTo describe treatment outcomes for rifampicin-resistant tuberculosis (Rr-TB) started on standard regimen and the frequency of acquired drug resistance in patients treated using the standard treatment regimen (STR) in Cameroon between 2015-2019.This is a retrospective cohort study. Rr-TB patients were initiated on the STR, including a fluoroquinolone (FQ), a second-line injectable drug (SLI), and companion drugs. In case of resistance to fluoroquinolones (FQr) at baseline, FQ, SLI and ethionamide were replaced by bedaquiline, delamanid, and linezolid in a modified treatment regimen (mTR), FQr-mTR. In case of resistance to SLI (SLIr) at baseline, SLI was replaced by linezolid (LZD), SLIr-mTR. Logistic regression and competing risk regression were used to estimate predictors of early (first eight weeks) mortality and overall mortality, respectively.METHODSThis is a retrospective cohort study. Rr-TB patients were initiated on the STR, including a fluoroquinolone (FQ), a second-line injectable drug (SLI), and companion drugs. In case of resistance to fluoroquinolones (FQr) at baseline, FQ, SLI and ethionamide were replaced by bedaquiline, delamanid, and linezolid in a modified treatment regimen (mTR), FQr-mTR. In case of resistance to SLI (SLIr) at baseline, SLI was replaced by linezolid (LZD), SLIr-mTR. Logistic regression and competing risk regression were used to estimate predictors of early (first eight weeks) mortality and overall mortality, respectively.Of 709 patients started on a standard regimen, treatment success occurred in 84.7% (587/693), 72.7% (8/11) and 100% (10/10) of patients treated with STR, FQr-mTR and SLIr-mTR as final regimens, respectively. Three (0.6%) patients acquired FQr during treatment. Early mortality occurred in 4.1% (29/709) and was associated with being HIV positive, male sex and being underweight. Overall mortality was associated with missing drug-susceptibility testing results at baseline, being HIV positive, age>40 and male sex.RESULTSOf 709 patients started on a standard regimen, treatment success occurred in 84.7% (587/693), 72.7% (8/11) and 100% (10/10) of patients treated with STR, FQr-mTR and SLIr-mTR as final regimens, respectively. Three (0.6%) patients acquired FQr during treatment. Early mortality occurred in 4.1% (29/709) and was associated with being HIV positive, male sex and being underweight. Overall mortality was associated with missing drug-susceptibility testing results at baseline, being HIV positive, age>40 and male sex.Programmatic management of Rr-TB, with additional second-line drug resistance treated with mTR, resulted in excellent treatment outcomes.CONCLUSIONProgrammatic management of Rr-TB, with additional second-line drug resistance treated with mTR, resulted in excellent treatment outcomes. |
| Author | Decroo, Tom Gils, Tinne Kuate, Albert Makondi, Danielle Lynen, Lutgarde André, Emmanuel Mbassa, Vincent Ngono, Annie Belinga, Edwige Tollo, Alphonse Noeske, Jürgen Piubello, Alberto Masumbe, Palmer Jouego, Christelle Géneviève Etoundi, Antoine |
| Author_xml | – sequence: 1 givenname: Christelle Géneviève orcidid: 0000-0002-2591-8438 surname: Jouego fullname: Jouego, Christelle Géneviève email: jouego.christelle@gmail.com organization: Cameroon National Tuberculosis Program (NTP), Mballa 2, BP 15 656 Yaoundé, Cameroun – sequence: 2 givenname: Tinne orcidid: 0000-0002-5518-9600 surname: Gils fullname: Gils, Tinne email: tgils@itg.be organization: Institute of Tropical Medicine, Department of Clinical Sciences, Unit of HIV and Tuberculosis, Nationalestraat 155, 2000 Antwerp, Belgium – sequence: 3 givenname: Alberto orcidid: 0000-0002-6937-3126 surname: Piubello fullname: Piubello, Alberto organization: Damien Foundation, Boulevard Leopold II 263, 1081 Koekelberg, Brussels, Belgium – sequence: 4 givenname: Vincent surname: Mbassa fullname: Mbassa, Vincent organization: Cameroon National Tuberculosis Program (NTP), Mballa 2, BP 15 656 Yaoundé, Cameroun – sequence: 5 givenname: Albert surname: Kuate fullname: Kuate, Albert organization: Cameroon National Tuberculosis Program (NTP), Mballa 2, BP 15 656 Yaoundé, Cameroun – sequence: 6 givenname: Annie surname: Ngono fullname: Ngono, Annie email: anniebissongono@pnlt.cm organization: Cameroon National Tuberculosis Program (NTP), Mballa 2, BP 15 656 Yaoundé, Cameroun – sequence: 7 givenname: Edwige surname: Belinga fullname: Belinga, Edwige email: abengmvondo@pnlt.cm organization: Cameroon National Tuberculosis Program (NTP), Mballa 2, BP 15 656 Yaoundé, Cameroun – sequence: 8 givenname: Antoine surname: Etoundi fullname: Etoundi, Antoine email: antoineetoundi@pnlt.cm organization: Cameroon National Tuberculosis Program (NTP), Mballa 2, BP 15 656 Yaoundé, Cameroun – sequence: 9 givenname: Alphonse surname: Tollo fullname: Tollo, Alphonse email: albertkuate@pnlt.cm organization: Cameroon National Tuberculosis Program (NTP), Mballa 2, BP 15 656 Yaoundé, Cameroun – sequence: 10 givenname: Danielle surname: Makondi fullname: Makondi, Danielle email: danieltollo@pnlt.cm organization: Cameroon National Tuberculosis Program (NTP), Mballa 2, BP 15 656 Yaoundé, Cameroun – sequence: 11 givenname: Emmanuel surname: André fullname: André, Emmanuel email: emmanuel.andre@uzleuven.be organization: Catholic University of Leuven, Laboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, UZ Herestraat 49, 3000 Leuven, Belgium – sequence: 12 givenname: Palmer orcidid: 0000-0002-2341-6813 surname: Masumbe fullname: Masumbe, Palmer email: masumbe.palmer@facsciences-uy1.cm organization: University of Yaoundé 1, Biotechnology centre, Molecular Diagnostic and Research Group, 11864 Yaoundé, Cameroon – sequence: 13 givenname: Lutgarde orcidid: 0000-0001-7183-4895 surname: Lynen fullname: Lynen, Lutgarde email: llynen@itg.be organization: Institute of Tropical Medicine, Department of Clinical Sciences, Unit of HIV and Tuberculosis, Nationalestraat 155, 2000 Antwerp, Belgium – sequence: 14 givenname: Jürgen orcidid: 0000-0002-7656-5070 surname: Noeske fullname: Noeske, Jürgen organization: Independent Consultant, Yaoundé, Cameroon – sequence: 15 givenname: Tom orcidid: 0000-0002-1205-1484 surname: Decroo fullname: Decroo, Tom email: tdecroo@itg.be organization: Institute of Tropical Medicine, Department of Clinical Sciences, Unit of HIV and Tuberculosis, Nationalestraat 155, 2000 Antwerp, Belgium |
| BookMark | eNqFkU9v1DAQxSNUJNrCF-CUI5cstuM4TsUFVfypVAkOvVuz9ng7S2IvtrdopX54vCxceignW8_zG_m9d9GchRiwad5ytuKMq_fbFW3JrQQTYsWmFePiRXPO9ai7fuD8rN4F4900cvGquch5yxiTSunz5vF7ipsEywKFbLtAgA0uGEobfZvIw7IjS6FLmCkXqHrZrzHZ_Ryr0P6ict8edQfJtQk3VNmWQnsNC6YYw1ULVS4p5h3aQg_Y2ngfU6nQ3h1eNy89zBnf_D0vm7vPn-6uv3a3377cXH-87aycZOnswH0vPefeu5GJSSvoVc8VkwhCsXGqT2C9ALnuJ1hr7lEjIp-UH_To-svm5rTWRdiaXaIF0sFEIPNHiGljIFX7M5qR95MUqB0HJQfHNFdeesuGEZ22WtVd7067din-3GMuZqFscZ4hYNxnI0Y-SCkm1ddRfRq11X5O6I2lUmOOoSSg2XBmjt2ZrTl2Z47dGTaZ2l1FxRP036-fhT6cIKxRPhAmky1hsOgo1fCrWXoev3qC25kCWZh_4OF_8G_7Z8tI |
| CitedBy_id | crossref_primary_10_1136_bmjgh_2024_015977 crossref_primary_10_1093_cid_ciac876 crossref_primary_10_1371_journal_pone_0306076 crossref_primary_10_1016_j_cegh_2024_101604 |
| Cites_doi | 10.1371/journal.pone.0238016 10.1038/s41598-019-48289-9 10.1016/S2213-2600(19)30473-4 10.3390/jcm9061873 10.1371/journal.pone.0261149 10.3201/eid2403.171362 10.5588/ijtld.19.0298 10.1093/jac/dkaa489 10.1016/S2352-3018(20)30101-6 10.1371/journal.pone.0132394 10.1056/NEJMoa1901814 10.1016/j.rmed.2019.105844 10.1056/NEJMoa1811867 10.1183/13993003.02250-2020 10.1136/bmjopen-2021-051521 10.5588/ijtld.17.0660 10.1164/rccm.201001-0077OC 10.1183/13993003.02383-2019 10.3390/jcm9010055 10.1093/cid/cix1138 10.5588/ijtld.17.0498 |
| ContentType | Journal Article |
| Copyright | 2022 Copyright © 2022. Published by Elsevier Ltd. |
| Copyright_xml | – notice: 2022 – notice: Copyright © 2022. Published by Elsevier Ltd. |
| DBID | 6I. AAFTH AAYXX CITATION 7X8 DOA |
| DOI | 10.1016/j.ijid.2022.09.012 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1878-3511 |
| EndPage | 88 |
| ExternalDocumentID | oai_doaj_org_article_713942e8d1a645d0816f4fc057ed8c86 10_1016_j_ijid_2022_09_012 S1201971222005112 |
| GroupedDBID | --- --K .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 29J 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 7X7 88E 8C1 8FI 8FJ 8FQ 8R4 8R5 AAEDW AAFWJ AAIKJ AALRI AAQFI AAQXK AARKO AAXUO AAYWO ABBQC ABFRF ABMAC ABUWG ABWVN ACGFO ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFJKZ AFKRA AFPKN AFPUW AFRHN AFTJW AGEKW AGHFR AGQPQ AGYEJ AHMBA AIGII AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN BAWUL BCNDV BENPR BPHCQ BR6 BVXVI CCPQU CS3 DIK DU5 DWQXO E3Z EBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FNPLU FYUFA G-Q GBLVA GROUPED_DOAJ GX1 HMCUK HVGLF HZ~ IHE IXB J1W KQ8 M1P M3C M3G M41 MO0 N9A O-L O9- OD- OK1 OO. OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO Q2X Q38 QTD R2- ROL RPZ RWL RXW SDF SDG SEL SES SEW SSZ TAE UKHRP UNMZH Z5R ~HD 6I. AACTN AAFTH AFCTW ALIPV RIG 9DU AAYXX AFFHD CITATION 7X8 |
| ID | FETCH-LOGICAL-c494t-c51f34f11ffd702986a3631604ea26079f11acf2a4b39ab81fe8eee196f587d3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 4 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000876603500009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1201-9712 1878-3511 |
| IngestDate | Fri Oct 03 12:45:42 EDT 2025 Sun Nov 09 12:55:49 EST 2025 Sat Nov 29 06:59:21 EST 2025 Tue Nov 18 22:32:58 EST 2025 Sun Apr 06 06:54:29 EDT 2025 Tue Oct 14 19:34:31 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Fluoroquinolone and second-line injectable resistance Cameroon Rr-TB Standard regimen |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c494t-c51f34f11ffd702986a3631604ea26079f11acf2a4b39ab81fe8eee196f587d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-5518-9600 0000-0001-7183-4895 0000-0002-2341-6813 0000-0002-2591-8438 0000-0002-7656-5070 0000-0002-6937-3126 0000-0002-1205-1484 |
| OpenAccessLink | https://doaj.org/article/713942e8d1a645d0816f4fc057ed8c86 |
| PQID | 2715442963 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_713942e8d1a645d0816f4fc057ed8c86 proquest_miscellaneous_2715442963 crossref_citationtrail_10_1016_j_ijid_2022_09_012 crossref_primary_10_1016_j_ijid_2022_09_012 elsevier_sciencedirect_doi_10_1016_j_ijid_2022_09_012 elsevier_clinicalkey_doi_10_1016_j_ijid_2022_09_012 |
| PublicationCentury | 2000 |
| PublicationDate | November 2022 2022-11-00 20221101 2022-11-01 |
| PublicationDateYYYYMMDD | 2022-11-01 |
| PublicationDate_xml | – month: 11 year: 2022 text: November 2022 |
| PublicationDecade | 2020 |
| PublicationTitle | International journal of infectious diseases |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
| References | Conradie, Diacon, Ngubane, Howell, Everitt, Crook (bib0004) 2020; 382 Ndlovu, Burton, Stewart, Bygrave, Roberts, Fajardo (bib0017) 2020; 7 Loutet, Davidson, Brown, Dedicoat, Thomas, Lalor (bib0015) 2018; 24 Wright, Zignol, Van, Falzon, Gerdes, Feldman (bib0034) 2009; 373 Ciza, Gils, Sawadogo, Decroo, Roggi, Piubello (bib0003) 2020; 9 World Health Organization (WHO). Definitions and reporting framework for tuberculosis –2013 revision. WHO/HTM/TB. 20 Avenue Appia, 1211 Geneva 27, Switzerland: 2014b. Nunn, Phillips, Meredith, Chiang, Conradie, Dalai (bib0020) 2019 (bib0029) 2022 Calmy, Ford, Meintjes (bib0002) 2018; 66 (bib0028) 2020 Kuaban, Pefura, Bava (bib0014) 2008; 12 Bigna, Noubiap, Agbor, Plottel, Billong, Ayong (bib0001) 2015; 10 Trébucq, Decroo, Van Deun, Piubello, Chiang, Koura (bib0026) 2020; 9 Trebucq, Schwoebel, Kashongwe, Bakayoko, Kuaban, Noeske (bib0027) 2018; 22 (bib0030) 2020; 4 Ngabonziza, Habimana, Decroo, Migambi, Dushime, Mazarati (bib0018) 2020; 24 Decroo, Jai, Aung, Hossain, Gumusboga, Ortuno-Gutierrez (bib0006) 2021 Core Development Team R (bib0005) 2020; 2 World Health Organization (WHO). Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. 20 Avenue Appia, 1211 Geneva 27, Switzerland: 2014a. Edessa, Adem, Hagos, Sisay (bib0011) 2021; 16 Ismail, Omar, Moultrie, Bhyat, Conradie, Enwerem (bib0013) 2021 Rigouts, Miotto, Schats, Lempens, Cabibbe, Galbiati (bib0023) 2019; 9 Decroo T, de Jong BC, Piubello A, Lynen L, Van Deun A. Tuberculosis treatment: one-shot approach or cascade of regimens? 2020a. 10.1016/S2213-2600(19)30473-4. Gomez, Siapka, Conradie, Ndjeka, Garfin, Lomtadze (bib0012) 2021; 11 Nimmo, Millard, Brien, Moodley, Van Dorp, Lutchminarain (bib0019) 2020; 55 Decroo, Kya Jai Maug, Hossain, Uwizeye, Gumusboga, Demeulenaere (bib0008) 2020; 15 Ministry of public health Republic of Cameroon. Programme national de lutte contre la tuberculose: Guide de prise en charge de la tuberculose chez l'enfant. 2020th ed. 2004. Piubello, Aït-khaled, Caminero, Chiang, Dlodlo, Fujiwara (bib0021) 2018; September Tahseen, Van Deun, De Jong, Decroo (bib0025) 2021; 76 World Health Organization (WHO). Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. 2017. Van Deun, Maug, Salim, Das, Sarker, Daru (bib0010) 2010; 182 Van Deun, Decroo, Piubello, De Jong, Lynen, Rieder (bib0009) 2018; 22 Piubello, Bassirou Souleymane, Hassane-Harouna, Yacouba, Lempens, Mohamed Assao-Neino (bib0022) 2020; 161 Souleymane, Piubello, Lawan, Hassane-Harouna, Assao-Neino, Soumana (bib0024) 2021; 57 Core Development Team R (10.1016/j.ijid.2022.09.012_bib0005) 2020; 2 Bigna (10.1016/j.ijid.2022.09.012_bib0001) 2015; 10 Gomez (10.1016/j.ijid.2022.09.012_bib0012) 2021; 11 Ismail (10.1016/j.ijid.2022.09.012_bib0013) 2021 Calmy (10.1016/j.ijid.2022.09.012_bib0002) 2018; 66 Van Deun (10.1016/j.ijid.2022.09.012_bib0009) 2018; 22 Piubello (10.1016/j.ijid.2022.09.012_bib0022) 2020; 161 Trébucq (10.1016/j.ijid.2022.09.012_bib0026) 2020; 9 10.1016/j.ijid.2022.09.012_bib0016 Decroo (10.1016/j.ijid.2022.09.012_bib0006) 2021 (10.1016/j.ijid.2022.09.012_bib0030) 2020; 4 Wright (10.1016/j.ijid.2022.09.012_bib0034) 2009; 373 Ngabonziza (10.1016/j.ijid.2022.09.012_bib0018) 2020; 24 10.1016/j.ijid.2022.09.012_bib0033 10.1016/j.ijid.2022.09.012_bib0032 10.1016/j.ijid.2022.09.012_bib0031 Edessa (10.1016/j.ijid.2022.09.012_bib0011) 2021; 16 Rigouts (10.1016/j.ijid.2022.09.012_bib0023) 2019; 9 Nimmo (10.1016/j.ijid.2022.09.012_bib0019) 2020; 55 Decroo (10.1016/j.ijid.2022.09.012_bib0008) 2020; 15 Kuaban (10.1016/j.ijid.2022.09.012_bib0014) 2008; 12 Souleymane (10.1016/j.ijid.2022.09.012_bib0024) 2021; 57 Piubello (10.1016/j.ijid.2022.09.012_bib0021) 2018; September Loutet (10.1016/j.ijid.2022.09.012_bib0015) 2018; 24 (10.1016/j.ijid.2022.09.012_bib0029) 2022 Ndlovu (10.1016/j.ijid.2022.09.012_bib0017) 2020; 7 Trebucq (10.1016/j.ijid.2022.09.012_bib0027) 2018; 22 Ciza (10.1016/j.ijid.2022.09.012_bib0003) 2020; 9 Tahseen (10.1016/j.ijid.2022.09.012_bib0025) 2021; 76 Conradie (10.1016/j.ijid.2022.09.012_bib0004) 2020; 382 10.1016/j.ijid.2022.09.012_bib0007 Nunn (10.1016/j.ijid.2022.09.012_bib0020) 2019 (10.1016/j.ijid.2022.09.012_bib0028) 2020 Van Deun (10.1016/j.ijid.2022.09.012_bib0010) 2010; 182 |
| References_xml | – volume: 66 start-page: S103 year: 2018 end-page: S105 ident: bib0002 article-title: The Persistent Challenge of Advanced HIV Disease and AIDS in the Era of Antiretroviral Therapy publication-title: Clinical Infectious Diseases – volume: 16 year: 2021 ident: bib0011 article-title: Incidence and predictors of mortality among persons receiving second-line tuberculosis treatment in sub-Saharan Africa: A meta-analysis of 43 cohort studies publication-title: Plos One – volume: 7 start-page: e514 year: 2020 end-page: e520 ident: bib0017 article-title: Framework for the implementation of advanced HIV disease diagnostics in sub-Saharan Africa: programmatic perspectives publication-title: The Lancet HIV – volume: 11 start-page: 51521 year: 2021 ident: bib0012 article-title: Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines publication-title: BMJ Open – volume: 161 year: 2020 ident: bib0022 article-title: Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements publication-title: Respiratory Medicine – volume: 76 start-page: 831 year: 2021 end-page: 835 ident: bib0025 article-title: Second-line injectable drugs for rifampicin-resistant tuberculosis: Better the devil we know? publication-title: Journal of Antimicrobial Chemotherapy – volume: 12 start-page: 1 year: 2008 end-page: 26 ident: bib0014 article-title: Early Mortality in New Patients on Treatment for Smear Positive Pulmonary Tuberculosis in Yaounde-Cameroon publication-title: Health Science Diseases – start-page: 6 year: 2022 ident: bib0029 article-title: Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis – year: 2021 ident: bib0013 article-title: Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study publication-title: The Lancet Infectious Diseases – volume: 373 year: 2009 ident: bib0034 article-title: Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance publication-title: WwwThelancetCom – volume: 182 start-page: 684 year: 2010 end-page: 692 ident: bib0010 article-title: Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis publication-title: American Journal of Respiratory and Critical Care Medicine – start-page: 1201 year: 2019 end-page: 1213 ident: bib0020 article-title: A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis publication-title: New England Journal of Medicine – volume: 22 start-page: 239 year: 2018 end-page: 245 ident: bib0009 article-title: Principles for constructing a tuberculosis treatment regimen: The role and definition of core and companion drugs publication-title: International Journal of Tuberculosis and Lung Disease – volume: September year: 2018 ident: bib0021 publication-title: Field guide for the management of drug-resistant tuberculosis – reference: World Health Organization (WHO). Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. 2017. – year: 2020 ident: bib0028 article-title: Consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment – volume: 9 year: 2019 ident: bib0023 article-title: Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations publication-title: Scientific Reports – volume: 2 year: 2020 ident: bib0005 publication-title: A Language and Environment for Statistical Computing – reference: Ministry of public health Republic of Cameroon. Programme national de lutte contre la tuberculose: Guide de prise en charge de la tuberculose chez l'enfant. 2020th ed. 2004. – volume: 57 year: 2021 ident: bib0024 article-title: High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss publication-title: European Respiratory Journal – volume: 24 start-page: 524 year: 2018 end-page: 533 ident: bib0015 article-title: Acquired resistance to antituberculosis drugs in England, wales, and Northern Ireland, 2000–2015 publication-title: Emerging Infectious Diseases – volume: 382 start-page: 893 year: 2020 end-page: 902 ident: bib0004 article-title: Treatment of Highly Drug-Resistant Pulmonary Tuberculosis publication-title: New England Journal of Medicine – volume: 24 start-page: 329 year: 2020 end-page: 339 ident: bib0018 article-title: Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda publication-title: International Journal of Tuberculosis and Lung Disease – volume: 22 start-page: 17 year: 2018 end-page: 25 ident: bib0027 article-title: Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries publication-title: International Journal of Tuberculosis and Lung Disease – reference: World Health Organization (WHO). Definitions and reporting framework for tuberculosis –2013 revision. WHO/HTM/TB. 20 Avenue Appia, 1211 Geneva 27, Switzerland: 2014b. – year: 2021 ident: bib0006 article-title: Bedaquiline can act as core drug in a standardized treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis publication-title: European Respiratory Journal – volume: 10 start-page: 1 year: 2015 end-page: 13 ident: bib0001 article-title: Early mortality during initial treatment of tuberculosis in patients co-infected with HIV at the Yaoundé Central Hospital, Cameroon: An 8-year retrospective cohort study (2006-2013) publication-title: PLoS ONE – volume: 9 start-page: 1 year: 2020 end-page: 15 ident: bib0003 article-title: Course of adverse events during short treatment regimen in patients with rifampicin-resistant tuberculosis in burundi publication-title: Journal of Clinical Medicine – volume: 55 year: 2020 ident: bib0019 article-title: Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients publication-title: European Respiratory Journal – reference: Decroo T, de Jong BC, Piubello A, Lynen L, Van Deun A. Tuberculosis treatment: one-shot approach or cascade of regimens? 2020a. 10.1016/S2213-2600(19)30473-4. – volume: 15 year: 2020 ident: bib0008 article-title: Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes publication-title: PLoS ONE – volume: 4 year: 2020 ident: bib0030 publication-title: Global Tuberculosis Report 2020 – volume: 9 start-page: 55 year: 2020 ident: bib0026 article-title: Short-course regimen for multidrug-resistant tuberculosis: A decade of evidence publication-title: Journal of Clinical Medicine – reference: World Health Organization (WHO). Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. 20 Avenue Appia, 1211 Geneva 27, Switzerland: 2014a. – ident: 10.1016/j.ijid.2022.09.012_bib0016 – volume: 373 year: 2009 ident: 10.1016/j.ijid.2022.09.012_bib0034 article-title: Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance publication-title: WwwThelancetCom – volume: September year: 2018 ident: 10.1016/j.ijid.2022.09.012_bib0021 – volume: 15 year: 2020 ident: 10.1016/j.ijid.2022.09.012_bib0008 article-title: Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes publication-title: PLoS ONE doi: 10.1371/journal.pone.0238016 – volume: 9 year: 2019 ident: 10.1016/j.ijid.2022.09.012_bib0023 article-title: Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations publication-title: Scientific Reports doi: 10.1038/s41598-019-48289-9 – ident: 10.1016/j.ijid.2022.09.012_bib0007 doi: 10.1016/S2213-2600(19)30473-4 – year: 2020 ident: 10.1016/j.ijid.2022.09.012_bib0028 – volume: 9 start-page: 1 year: 2020 ident: 10.1016/j.ijid.2022.09.012_bib0003 article-title: Course of adverse events during short treatment regimen in patients with rifampicin-resistant tuberculosis in burundi publication-title: Journal of Clinical Medicine doi: 10.3390/jcm9061873 – volume: 4 year: 2020 ident: 10.1016/j.ijid.2022.09.012_bib0030 – volume: 16 year: 2021 ident: 10.1016/j.ijid.2022.09.012_bib0011 article-title: Incidence and predictors of mortality among persons receiving second-line tuberculosis treatment in sub-Saharan Africa: A meta-analysis of 43 cohort studies publication-title: Plos One doi: 10.1371/journal.pone.0261149 – volume: 24 start-page: 524 year: 2018 ident: 10.1016/j.ijid.2022.09.012_bib0015 article-title: Acquired resistance to antituberculosis drugs in England, wales, and Northern Ireland, 2000–2015 publication-title: Emerging Infectious Diseases doi: 10.3201/eid2403.171362 – start-page: 6 year: 2022 ident: 10.1016/j.ijid.2022.09.012_bib0029 – volume: 24 start-page: 329 year: 2020 ident: 10.1016/j.ijid.2022.09.012_bib0018 article-title: Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda publication-title: International Journal of Tuberculosis and Lung Disease doi: 10.5588/ijtld.19.0298 – ident: 10.1016/j.ijid.2022.09.012_bib0032 – volume: 76 start-page: 831 year: 2021 ident: 10.1016/j.ijid.2022.09.012_bib0025 article-title: Second-line injectable drugs for rifampicin-resistant tuberculosis: Better the devil we know? publication-title: Journal of Antimicrobial Chemotherapy doi: 10.1093/jac/dkaa489 – volume: 7 start-page: e514 year: 2020 ident: 10.1016/j.ijid.2022.09.012_bib0017 article-title: Framework for the implementation of advanced HIV disease diagnostics in sub-Saharan Africa: programmatic perspectives publication-title: The Lancet HIV doi: 10.1016/S2352-3018(20)30101-6 – volume: 10 start-page: 1 year: 2015 ident: 10.1016/j.ijid.2022.09.012_bib0001 article-title: Early mortality during initial treatment of tuberculosis in patients co-infected with HIV at the Yaoundé Central Hospital, Cameroon: An 8-year retrospective cohort study (2006-2013) publication-title: PLoS ONE doi: 10.1371/journal.pone.0132394 – volume: 382 start-page: 893 year: 2020 ident: 10.1016/j.ijid.2022.09.012_bib0004 article-title: Treatment of Highly Drug-Resistant Pulmonary Tuberculosis publication-title: New England Journal of Medicine doi: 10.1056/NEJMoa1901814 – volume: 161 year: 2020 ident: 10.1016/j.ijid.2022.09.012_bib0022 article-title: Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements publication-title: Respiratory Medicine doi: 10.1016/j.rmed.2019.105844 – start-page: 1201 year: 2019 ident: 10.1016/j.ijid.2022.09.012_bib0020 article-title: A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis publication-title: New England Journal of Medicine doi: 10.1056/NEJMoa1811867 – volume: 57 year: 2021 ident: 10.1016/j.ijid.2022.09.012_bib0024 article-title: High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss publication-title: European Respiratory Journal doi: 10.1183/13993003.02250-2020 – volume: 12 start-page: 1 year: 2008 ident: 10.1016/j.ijid.2022.09.012_bib0014 article-title: Early Mortality in New Patients on Treatment for Smear Positive Pulmonary Tuberculosis in Yaounde-Cameroon publication-title: Health Science Diseases – volume: 11 start-page: 51521 year: 2021 ident: 10.1016/j.ijid.2022.09.012_bib0012 article-title: Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines publication-title: BMJ Open doi: 10.1136/bmjopen-2021-051521 – volume: 22 start-page: 239 year: 2018 ident: 10.1016/j.ijid.2022.09.012_bib0009 article-title: Principles for constructing a tuberculosis treatment regimen: The role and definition of core and companion drugs publication-title: International Journal of Tuberculosis and Lung Disease doi: 10.5588/ijtld.17.0660 – volume: 182 start-page: 684 year: 2010 ident: 10.1016/j.ijid.2022.09.012_bib0010 article-title: Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis publication-title: American Journal of Respiratory and Critical Care Medicine doi: 10.1164/rccm.201001-0077OC – volume: 55 year: 2020 ident: 10.1016/j.ijid.2022.09.012_bib0019 article-title: Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients publication-title: European Respiratory Journal doi: 10.1183/13993003.02383-2019 – volume: 9 start-page: 55 year: 2020 ident: 10.1016/j.ijid.2022.09.012_bib0026 article-title: Short-course regimen for multidrug-resistant tuberculosis: A decade of evidence publication-title: Journal of Clinical Medicine doi: 10.3390/jcm9010055 – ident: 10.1016/j.ijid.2022.09.012_bib0031 – volume: 66 start-page: S103 year: 2018 ident: 10.1016/j.ijid.2022.09.012_bib0002 article-title: The Persistent Challenge of Advanced HIV Disease and AIDS in the Era of Antiretroviral Therapy publication-title: Clinical Infectious Diseases doi: 10.1093/cid/cix1138 – year: 2021 ident: 10.1016/j.ijid.2022.09.012_bib0006 article-title: Bedaquiline can act as core drug in a standardized treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis publication-title: European Respiratory Journal – ident: 10.1016/j.ijid.2022.09.012_bib0033 – year: 2021 ident: 10.1016/j.ijid.2022.09.012_bib0013 article-title: Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study publication-title: The Lancet Infectious Diseases – volume: 2 year: 2020 ident: 10.1016/j.ijid.2022.09.012_bib0005 – volume: 22 start-page: 17 year: 2018 ident: 10.1016/j.ijid.2022.09.012_bib0027 article-title: Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries publication-title: International Journal of Tuberculosis and Lung Disease doi: 10.5588/ijtld.17.0498 |
| SSID | ssj0004668 |
| Score | 2.3568487 |
| Snippet | To describe treatment outcomes for rifampicin-resistant tuberculosis (Rr-TB) started on standard regimen and the frequency of acquired drug resistance in... Objectives: To describe treatment outcomes for rifampicin-resistant tuberculosis (Rr-TB) started on standard regimen and the frequency of acquired drug... |
| SourceID | doaj proquest crossref elsevier |
| SourceType | Open Website Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 81 |
| SubjectTerms | Cameroon Fluoroquinolone and second-line injectable resistance Rr-TB Standard regimen |
| Title | Programmatic management of rifampicin-resistant tuberculosis with standard regimen in Cameroon: a retrospective cohort study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1201971222005112 https://dx.doi.org/10.1016/j.ijid.2022.09.012 https://www.proquest.com/docview/2715442963 https://doaj.org/article/713942e8d1a645d0816f4fc057ed8c86 |
| Volume | 124 |
| WOSCitedRecordID | wos000876603500009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1878-3511 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004668 issn: 1201-9712 databaseCode: DOA dateStart: 19960101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1BT90wDI4YQtMkhDa2iQcMBWm3qVqTpm3CbUMgDgxxQOjdojR1pCJei0ofp_34OUlbjR3gsmsaN23sOHZifybkK0tTa1LlEq44OiisqBMlrUiMy0tWVcCKECB7e1leXcnlUl3_VerLx4RFeOA4cd_RiVKCg6yZKURe-zoRTjiLZgbU0soAto1Wz-RMzRmRMQkOt7dElYyP6TIxsqu5azxGKOcB4ZTxZ1tSQO5_tjP9o6PDxnP-nuyMFiP9Eb_0A9mAdpe8_TXeie-S7XjyRmNC0Ufy-zqGXAUsVrqaw1to52jfOLN68IQJutnedMT2YV1Bb9f3HTZQfy5Lp_MF6ss2IC1tWnpqVoBWdntCDTYPfTflaFJfY7cfaACq_URuzs9uTi-SscZCYoUSQ2Jz5jLhGHOuLj0ce2GyImNFKsCgq1MqfGSs40ZUmTKVZA4kAOC6dbks6-wz2Wy7FvYIzaWsUovsRQ0ikKyCGmoOueUCwKliQdg0y9qO-OO-DMa9ngLN7rTnjPac0anSyJkF-TbTPET0jRd7__TMm3t65OzQgPKkR3nSr8nTgmQT6_WUnIrqFF_UvDh0PlONpks0SV6lO56kS-O69pc1poVu_ah56XGSOOrH_f_xWwfknR82ZlEeks2hX8MXsmWfhuaxPyJvyqU8CkvoD-RaH1w |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Programmatic+management+of+rifampicin-resistant+tuberculosis+with+standard+regimen+in+Cameroon%3A+a+retrospective+cohort+study&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Jouego%2C+Christelle+G%C3%A9nevi%C3%A8ve&rft.au=Gils%2C+Tinne&rft.au=Piubello%2C+Alberto&rft.au=Mbassa%2C+Vincent&rft.date=2022-11-01&rft.issn=1878-3511&rft.eissn=1878-3511&rft.volume=124&rft.spage=81&rft_id=info:doi/10.1016%2Fj.ijid.2022.09.012&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon |